Sex: M
Vaccine: COVID19, UNK
Symptoms: Hypersensitivity, Immunisation, Pain, Psychomotor hyperactivity, Rheumatoid arthritis
Clinical narrative: Diabetic; Rheumatoid arthritis attacking; the third vaccination; Pain in shoulder; immune system went into hyper activity , body was on fire; body was in pain; Hidradenitis suppurativa was bleeding; allergies came back; body was producing more sugar; The initial case was missing the following minimum criteria: [(no suspect product)]. Upon receipt of follow-up information on [24Nov2021], this case now contains all required information to be considered valid.  This is a solicited report received from contactable reporter(s) (Consumer or other non HCP) for a sponsored program. The reporter is the patient. Other Case identifier(s): 21K-163-4102526-00 (AbbVie).  A 66 year-old male patient received bnt162b2 (BNT162B2), intramuscular (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous (Lot number: 1146181) at citrate free for hidradenitis, ankylosing spondylitis. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 Immunization; Bnt162b2 (DOSE 2, SINGLE), for COVID-19 Immunization. The following information was reported: IMMUNISATION (non-serious), outcome "unknown", described as "the third vaccination"; DIABETES MELLITUS (medically significant), outcome "unknown", described as "Diabetic"; RHEUMATOID ARTHRITIS (medically significant), outcome "unknown", described as "Rheumatoid arthritis attacking"; ARTHRALGIA (non-serious), outcome "recovered", described as "Pain in shoulder"; PSYCHOMOTOR HYPERACTIVITY (non-serious), outcome "unknown", described as "immune system went into hyper activity , body was on fire"; PAIN (non-serious), outcome "unknown", described as "body was in pain"; HIDRADENITIS (non-serious), outcome "unknown", described as "Hidradenitis suppurativa was bleeding"; HYPERSENSITIVITY (non-serious), outcome "unknown", described as "allergies came back"; BLOOD GLUCOSE INCREASED (non-serious), outcome "recovered", described as "body was producing more sugar". The patient underwent the following laboratory tests and procedures: blood glucose: more, notes: body was producing more sugar. The action taken for adalimumab was unknown.  The reporter's assessment of the causal relationship of the event with the suspect product was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information in the case report, a possible causal association between the events and suspect drug BNT162B2 cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.